Sarah Hartz is a Psychiatry physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Barnes Jewish Hospital Plz
Dept Psychiatry
Saint Louis, MO 631101003
Telephone
314-286-1700Registry record last updated 17 Apr 2025.
Clinical trials
- Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20251 payment
- ABBVIE INC.Program year20254 payments
- Janssen Pharmaceuticals, IncProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
99%Benzodiazepine19%Clonazepam68%Alprazolam12%Lorazepam12%Diazepam8%Part D<11 patientsAtypical Antipsychotic16.3%Clozapine18%Quetiapine Fumarate16%Aripiprazole14%Invega Sustenna12%Olanzapine12%Risperidone11%Paliperidone Er9%Olanzapine Odt8%Part D<11 patients+ 16 more classes in this area
Blood & clotting
1%P2Y12 inhibitor1%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:
- Returning AD biomarker Results to Community Dwelling Older Adults: Testing Modalities and Impact
Washington University
FY2025$674,607R01AG084723 - Returning AD biomarker Results to Community Dwelling Older Adults: Testing Modalities and Impact
Washington University
FY2024$715,539R01AG084723 - Returning Research Results that Indicate Risk of Alzheimer Disease to Healthy Participants in Longitudinal Studies
Washington University
FY2024$579,754R01AG065234
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”